The global market for Oral GLP-1 Drug was estimated to be worth US$ 1508 million in 2025 and is projected to reach US$ 3150 million, growing at a CAGR of 12.0% from 2026 to 2032.
Global Market Research Publisher QYResearch (QY Research) announces the release of its latest report “Oral GLP-1 Drug – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”. Based on 2025 market situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Oral GLP-1 Drug market, including market size, market share, market volume, demand, industry development status, and forecasts for the next few years.
The report provides advanced statistics and information on global market conditions and studies the strategic patterns adopted by renowned players across the globe. As the market is constantly changing, the report explores competition, supply and demand trends, as well as the key factors that contribute to its changing demands across many markets.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/6726207/oral-glp-1-drug
Oral GLP-1 Drugs Market Summary
Oral GLP-1 drugs are tablet-based incretin therapies that activate the GLP-1 receptor to reduce appetite, improve satiety and support long-term weight reduction without injection. Compared with injectable GLP-1 products, oral drugs may expand access among needle-averse patients and primary-care users, but their commercial success depends on efficacy, gastrointestinal tolerability, dosing restrictions, reimbursement and large-scale API/formulation capacity.
According to the new market research report “Global Oral GLP-1 Drugs Market Report 2026”, published by QYResearch, the global Sodium Sulfate market size is projected to reach USD 3,150 million by 2032, at a CAGR of 12% during the forecast period.
Market Overview
The oral GLP-1 drug market is rapidly evolving from a supplementary dosage form for diabetes treatment into a broader therapeutic market covering type 2 diabetes, obesity and cardiometabolic risk management. The key market logic is to convert GLP-1 therapy, historically dominated by injectables, into a more acceptable oral format suitable for long-term use. Novo Nordisk’s Rybelsus is already used as oral semaglutide for type 2 diabetes and received an expanded U.S. approval in 2025 for cardiovascular risk reduction in high-risk adults with type 2 diabetes, while the approval of the Wegovy pill in December 2025 marked the entry of oral GLP-1 therapy into the mainstream obesity market. Eli Lilly’s Foundayo, orforglipron, was approved by the FDA in April 2026 for long-term weight management in adults with obesity or overweight with related comorbidities, and its small-molecule profile allows dosing without food or water restrictions. Overall, oral GLP-1 drugs are unlikely to fully replace injectables, but they will meaningfully expand access among patients who are injection-averse, need moderate weight loss, require long-term maintenance therapy, or are managed in broader chronic-disease settings.
Regional Analysis
The United States is the fastest-moving commercial market for oral GLP-1 drugs, supported by rapid regulatory approvals, strong patient demand, and a payer system that can support premium obesity and diabetes therapies. Both Novo Nordisk’s Wegovy pill and Eli Lilly’s Foundayo were first approved in the U.S., making the country the most important market for pricing, access strategy and real-world demand validation. Europe is moving more gradually, but Novo Nordisk has already submitted once-daily oral semaglutide 25 mg for obesity to the EMA and other regulators, which could expand the European GLP-1 market from injectables to oral formulations if approved. China, Japan and other Asian markets have large diabetes and overweight populations, but adoption will be shaped by reimbursement pressure, local price sensitivity, domestic innovation and long-term adherence. Emerging markets may become attractive if oral GLP-1 drugs can offer lower delivery complexity, more stable supply and better convenience than injectable alternatives.
Competitive Landscape
The competitive landscape of oral GLP-1 drugs is highly concentrated, with key entering companies including Novo Nordisk, Eli Lilly, Pfizer, Roche/Chugai, AstraZeneca/Eccogene, Structure Therapeutics, Viking Therapeutics, Terns Pharmaceuticals and Hengrui Pharma. Among them, Novo Nordisk and Eli Lilly are the clear commercial leaders, as Novo Nordisk has built an early oral semaglutide franchise through Rybelsus and the Wegovy pill, while Eli Lilly has differentiated itself with the small-molecule GLP-1 orforglipron. Lilly’s orforglipron has shown strong clinical momentum, including head-to-head data in type 2 diabetes where it delivered greater A1C and weight reduction than oral semaglutide 14 mg, reinforcing its competitive positioning. Pfizer’s discontinuation of danuglipron in April 2025 also shows that oral GLP-1 development remains technically demanding, with safety, tolerability and dose optimization acting as major barriers. Future competition will be determined not only by oral administration, but also by weight-loss efficacy, gastrointestinal tolerability, cardiovascular evidence, dosing convenience, manufacturing cost, reimbursement access and global supply capability.
The report provides a detailed analysis of the market size, growth potential, and key trends for each segment. Through detailed analysis, industry players can identify profit opportunities, develop strategies for specific customer segments, and allocate resources effectively.
The Oral GLP-1 Drug market is segmented as below:
By Company
Novo Nordisk
Eli Lilly and Company
Segment by Type
Oral Peptide GLP-1
Oral Small-Molecule GLP-1
Segment by Application
Obesity Care
Diabetes Care
Others
Each chapter of the report provides detailed information for readers to further understand the Oral GLP-1 Drug market:
Chapter 1: Introduces the report scope of the Oral GLP-1 Drug report, global total market size (valve, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry. (2021-2032)
Chapter 2: Detailed analysis of Oral GLP-1 Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc. (2021-2026)
Chapter 3: Provides the analysis of various Oral GLP-1 Drug market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments. (2021-2032)
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.(2021-2032)
Chapter 5: Sales, revenue of Oral GLP-1 Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world..(2021-2032)
Chapter 6: Sales, revenue of Oral GLP-1 Drug in country level. It provides sigmate data by Type, and by Application for each country/region.(2021-2032)
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc. (2021-2026)
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
Other relevant reports of QYResearch:
Global Oral GLP-1 Drug Sales Market Report, Competitive Analysis and Regional Opportunities 2026-2032
Global Oral GLP-1 Drug Market Outlook, In‑Depth Analysis & Forecast to 2032
Global Oral GLP-1 Drug Market Research Report 2026
Benefits of purchasing QYResearch report:
Competitive Analysis: QYResearch provides in-depth Oral GLP-1 Drug competitive analysis, including information on key company profiles, new entrants, acquisitions, mergers, large market shear, opportunities, and challenges. These analyses provide clients with a comprehensive understanding of market conditions and competitive dynamics, enabling them to develop effective market strategies and maintain their competitive edge.
Industry Analysis: QYResearch provides Oral GLP-1 Drug comprehensive industry data and trend analysis, including raw material analysis, market application analysis, product type analysis, market demand analysis, market supply analysis, downstream market analysis, and supply chain analysis.
and trend analysis. These analyses help clients understand the direction of industry development and make informed business decisions.
Market Size: QYResearch provides Oral GLP-1 Drug market size analysis, including capacity, production, sales, production value, price, cost, and profit analysis. This data helps clients understand market size and development potential, and is an important reference for business development.
The report provides a detailed analysis of the market size, growth potential, and key trends for each segment. Through detailed analysis, industry players can identify profit opportunities, develop strategies for specific customer segments, and allocate resources effectively.
The Oral GLP-1 Drug market is segmented as below:
By Company
Novo Nordisk
Eli Lilly and Company
Segment by Type
Oral Peptide GLP-1
Oral Small-Molecule GLP-1
Segment by Application
Obesity Care
Diabetes Care
Others
Each chapter of the report provides detailed information for readers to further understand the Oral GLP-1 Drug market:
Chapter 1: Introduces the report scope of the Oral GLP-1 Drug report, global total market size (valve, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry. (2021-2032)
Chapter 2: Detailed analysis of Oral GLP-1 Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc. (2021-2026)
Chapter 3: Provides the analysis of various Oral GLP-1 Drug market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments. (2021-2032)
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.(2021-2032)
Chapter 5: Sales, revenue of Oral GLP-1 Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world..(2021-2032)
Chapter 6: Sales, revenue of Oral GLP-1 Drug in country level. It provides sigmate data by Type, and by Application for each country/region.(2021-2032)
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc. (2021-2026)
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
Benefits of purchasing QYResearch report:
Competitive Analysis: QYResearch provides in-depth Oral GLP-1 Drug competitive analysis, including information on key company profiles, new entrants, acquisitions, mergers, large market shear, opportunities, and challenges. These analyses provide clients with a comprehensive understanding of market conditions and competitive dynamics, enabling them to develop effective market strategies and maintain their competitive edge.
Industry Analysis: QYResearch provides Oral GLP-1 Drug comprehensive industry data and trend analysis, including raw material analysis, market application analysis, product type analysis, market demand analysis, market supply analysis, downstream market analysis, and supply chain analysis.
and trend analysis. These analyses help clients understand the direction of industry development and make informed business decisions.
Market Size: QYResearch provides Oral GLP-1 Drug market size analysis, including capacity, production, sales, production value, price, cost, and profit analysis. This data helps clients understand market size and development potential, and is an important reference for business development.
Other relevant reports of QYResearch:
Global Oral GLP-1 Drug Sales Market Report, Competitive Analysis and Regional Opportunities 2026-2032
Global Oral GLP-1 Drug Market Outlook, In‑Depth Analysis & Forecast to 2032
Global Oral GLP-1 Drug Market Research Report 2026
To contact us and get this report: https://www.qyresearch.com/contact-us
About Us：
QYResearch founded in California, USA in 2007, which is a leading global market research and consulting company. Our primary business include market research reports, custom reports, commissioned research, IPO consultancy, business plans, etc. With over 19 years of experience and a dedicated research team, we are well placed to provide useful information and data for your business, and we have established offices in 7 countries (include United States, Germany, Switzerland, Japan, Korea, China and India) and business partners in over 30 countries. We have provided industrial information services to more than 60,000 companies in over the world.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
